Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
HYPAZ: Hypertension Induced by Pazopanib
NCT01392352 · Cambridge University Hospitals NHS Foundation Trust · PHASE2 · terminated · last registry update 2020-02-13 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Following DMC review, due to slow recruitment of evaluable patients.” | – | Registry record, Cambridge University Hospitals NHS Foundation Trust |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF1R in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-07-14Results posted on the registry: Washington University School of Medicine, Pazopanib (NCT02193152)
- 2020-07-14Also stopped (terminated): Washington University School of Medicine, Pazopanib (NCT02193152)
- 2020-03-05Also stopped (terminated): Daiichi Sankyo, PLX3397 + Pembrolizumab (NCT02452424)
- 2019-10-09Results posted on the registry: Daiichi Sankyo, PLX3397 + Pembrolizumab (NCT02452424)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision